FGFR2 Gene Genetic Test for Craniofacial-Skeletal-Dermatologic Dysplasia in UAE | 2,800 AED | DHA Licensed

Executive Summary & Core Metrics

TRUSTED Executive Summary: This definitive NGS test targets the entire FGFR2 gene with 99.9% analytical sensitivity and specificity, processed in our ISO 9001:2015 certified facility. Premium hospital-grade home collection via ISO‑certified cold‑chain logistics, VIP mobile phlebotomy, and same‑day insurance verification via WhatsApp. Post‑test clinical guidance by a DHA‑licensed Consultant Medical Genetics specialist ensures accurate result interpretation.

✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS & Sanger Confirmation
✅ Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain, VIP Mobile Phlebotomy
✅ Clinical Guidance: Telephonic Post‑Test Result Interpretation by a DHA‑Certified Consultant
✅ Insurance: Direct Billing Verification within 30 minutes – WhatsApp +971 54 548 8731

Test Overview & Methodology

The FGFR2 gene NGS test is a high‑resolution genetic assay that detects pathogenic variants responsible for a spectrum of craniofacial‑skeletal‑dermatologic dysplasias, including Apert, Pfeiffer, and Crouzon syndromes. It empowers clinicians with a precise molecular diagnosis in 3–4 weeks, enabling targeted management and family counseling.

Feature	Our Test (NGS FGFR2 Panel)	Closest Alternative (Sanger Sequencing)
Precision	Whole‑gene coverage with CNV detection	Targeted exon analysis only
Method	Next‑Generation Sequencing (NGS) + Sanger confirmation	Individual exon Sanger sequencing
Speed	3–4 Weeks from sample receipt	6–8 Weeks typical

Physician Insight & Safety Protocols

“This NGS‑based assay provides comprehensive coverage of the FGFR2 gene, enabling detection of pathogenic variants that underlie complex craniofacial‑skeletal‑dermatologic syndromes. Integrating molecular findings with thorough clinical evaluation and genetic counseling is essential to translate genomic data into a personalized care pathway that prioritizes patient safety and informed decision‑making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication & Clinical Context

Results from this genetic test should never be used as the sole basis to discontinue or modify prescribed therapies. Always consult your treating physician before making any changes to your medication regimen or treatment plan.

Exclusion Criteria & Emergency Red Flags

Exclusion: Active febrile illness, inability to provide informed consent, or minors without a legal guardian present.
Exclusion: Patient currently on high‑dose anticoagulants (relative; requires medical clearance).
ER Red Flag: Sudden severe headache, visual disturbances, or vomiting in a patient with known craniofacial syndrome – seek immediate emergency care.
ER Red Flag: Acute respiratory distress or signs of raised intracranial pressure (bulging fontanelle in infants) – call 998.

Patient FAQ & Clinical Guidance

1. What is the FGFR2 gene NGS test and why is it needed?

Fast Answer: This advanced Genetic Test analyzes the entire FGFR2 gene for pathogenic variants linked to craniofacial‑skeletal‑dermatologic dysplasia, providing a precise diagnosis in just 3–4 weeks. It is recommended for patients with clinical signs such as craniosynostosis, midface hypoplasia, syndactyly, or severe acneiform eruptions, and for at‑risk family members seeking carrier or predictive testing.

2. Who should consider this genetic test?

Fast Answer: Individuals with a family history of FGFR2‑related syndromes, newborns with suggestive physical features, and adults with unexplained craniofacial or skeletal anomalies are prime candidates for this comprehensive DNA analysis. Genetic counseling is mandatory before testing to ensure informed consent and accurate pedigree assessment.

3. How is the sample collected and what is the process?

Fast Answer: Our VIP home collection team draws a small blood sample (or uses a painless FTA card finger‑prick) via a cold‑chain enabled kit, delivering it to our ISO‑certified lab within hours. You receive a digital report and a teleconsultation with a genetics specialist to explain the findings, all strictly confidential under UAE PDPL.

UAE Regulatory & Data Privacy Adherence

Your genetic data is protected under UAE law.

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Genetic information is classified as sensitive personal data, stored on encrypted UAE‑based servers, and processed only with your explicit, informed consent.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: All digital health records, including genomic test results, are transmitted and stored in compliance with UAE ICT security standards to prevent unauthorized access.
Federal Decree-Law No. 4 of 2016 on Medical Liability: Clinical testing, patient consent, and result disclosure follow the medical liability framework to ensure safety, accountability, and the right to informed medical decisions.
ISO 9001:2015 Certification: Laboratory processes certified by INT/EGQ/2509DA/3139, guaranteeing consistent quality management from pre‑analytical to post‑analytical phases.

Clinical & Logistical Metadata

Test Name	FGFR2 Gene Genetic Test for Craniofacial-Skeletal-Dermatologic Dysplasia
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood or Dried Blood Spot (FTA Card)
Methodology Used	Next-Generation Sequencing (NGS) with Sanger Confirmation
ICD-10-CM Code	Q87.0 (Craniofacial syndromes), Q75.1 (Crouzon syndrome)
LOINC Code	81261-5
DHA Facility License & Laboratory Address Invariants	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE